683 completed, 104 terminated, 71 recruiting, 65 unknown. 1023 Phase 2, 123 Phase 1, 70 Phase 3.
Follow Bronchial Diseases: new trials by email Literature Review of Bronchial Diseases trials Research Report on Bronchial Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function | Phase 2 | Not yet recruiting | Foresee Pharmaceuticals Co., Ltd. | 135 | 2027-03-01 | 2026-07-20 |
| Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy | Phase 2 | Withdrawn | Boston Children's Hospital | 2027-02-01 | 2024-11-26 | |
| Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) Slow Release DHEA, Placebo - Asthma | Phase 2 | Not yet recruiting | Indiana University | 30 | 2027-01-01 | 2026-02-27 |
| Nebulized Ketamine for Severe Asthma Attacks in Children Ketamine (1 mg/kg), Placebo - Asthma Acute, Exacerbation of Allergic Asthma | Phase 2 | Not yet recruiting | Sultan Qaboos University | 60 | 2027-01-01 | 2026-07-27 |
| Ginger's Therapeutic Potential in Asthma Ginger Extract, Placebo - Asthma | Phase 2 | Not yet recruiting | Emily DiMango, MD | 32 | 2026-11-01 | 2026-08-28 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma JNJ-95597528, Placebo - Asthma | Phase 2 | Not yet recruiting | Janssen Research & Development, LLC | 440 | 2026-10-29 | 2026-09-25 |
| Rademikibart IV for Acute Asthma and COPD Exacerbation Rademikibart - Asthma Acute, COPD Exacerbation Acute | Phase 2 | Recruiting | Connect Biopharm LLC | 40 | 2026-08-21 | 2026-10-27 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Brenipatide, Placebo, Standard of Care - Pulmonary Disease, Chronic Obstructive | Phase 2 | Recruiting | Eli Lilly and Company | 606 | 2026-08-07 | 2026-10-08 |
| Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma Dexamethasone (0.6mg/kg; Max 16mg) Once Daily, Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours, Methylprednisolone - Asthma (Diagnosis) | Phase 2 | Recruiting | Johns Hopkins All Children's Hospital | 159 | 2026-08-01 | 2026-08-12 |
| A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis Galvokimig, Placebo - Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | Phase 2 | Recruiting | UCB Biopharma SRL | 402 | 2026-07-27 | 2026-10-27 |
| A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma Frevecitinib, Placebo - Severe Asthma | Phase 2 | Recruiting | Kinaset Therapeutics Inc | 512 | 2026-07-16 | 2026-07-28 |
| To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Recruiting | Expedition Therapeutics, Inc | 600 | 2026-06-30 | 2026-10-28 |
| A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study KT-621 - Asthma (Diagnosis) | Phase 2 | Recruiting | Kymera Therapeutics, Inc. | 264 | 2026-06-25 | 2026-10-07 |
| Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients Tezepelumab - Bronchiolitis Obliterans Syndrome (BOS), HSCT | Phase 2 | Recruiting | Hopital Foch | 36 | 2026-06-24 | 2026-08-18 |
| Study of AHB-171 in Chronic Hepatitis B Participants AHB-171 Injection - Hepatitis B, Chronic (CHB) | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 138 | 2026-06-24 | 2026-07-21 |
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis SAR445399, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Suspended | Sanofi | 70 | 2026-06-08 | 2026-07-29 |
| Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare, Placebo nebulization (5 mL normal saline) plus standard asthma care - Asthma Acute, Asthma Attack | Phase 2 | Recruiting | Oman Medical Speciality Board | 100 | 2026-05-30 | 2026-10-19 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Efficacy of L-menthol on Breathlessness in Asthma L-menthol, Placebo - Asthma | Phase 2 | Recruiting | Region Skane | 20 | 2026-05-07 | 2026-08-19 |
Showing 20 of 1023. Sign in to see all of them.
Asthma (667) · Bronchiolitis Obliterans Syndrome (205) · Pulmonary Disease, Chronic Obstructive (70) · Lung Diseases (37) · Bronchiectasis (36) · Bronchitis, Chronic (36) · Hypersensitivity (29) · Respiratory Tract Diseases (29) · Graft vs Host Disease (27) · Bronchiolitis (26) · Bronchiolitis Obliterans (22) · Bronchial Neoplasms (20) · Emphysema (18) · Leukemia (18) · Lung Neoplasms (18)
Respiratory Tract Diseases (994) · Lung Diseases, Obstructive (950) · Lung Diseases (949) · Immune System Diseases (882) · Hypersensitivity, Immediate (678) · Respiratory Hypersensitivity (671) · Hypersensitivity (654) · Bronchitis (278) · Bronchiolitis (222) · Pathological Conditions, Signs and Symptoms (215) · Organizing Pneumonia (206) · Bronchiolitis Obliterans (200) · Graft vs Host Disease (180) · Pathologic Processes (148)
Formoterol Fumarate (37) · montelukast (36) · Fluticasone (34) · Albuterol (30) · Budesonide (19) · Beclomethasone (16) · Omalizumab (14) · Saline Solution (13) · Mometasone Furoate (12) · Prednisone (11) · Tiotropium Bromide (11) · fluticasone furoate (11) · Cholecalciferol (10) · Fluticasone-Salmeterol Drug Combination (10) · Rituximab (10)
GlaxoSmithKline (65) · Novartis Pharmaceuticals (48) · AstraZeneca (46) · Boehringer Ingelheim (31) · Chiesi Farmaceutici S.p.A. (25) · Sanofi (14) · MedImmune LLC (12) · National Institute of Allergy and Infectious Diseases (NIAID) (12) · Amphastar Pharmaceuticals, Inc. (10) · Genentech, Inc. (10) · Novartis (10) · Teva Branded Pharmaceutical Products R&D, Inc. (10) · Hoffmann-La Roche (9) · Merck Sharp & Dohme LLC (9) · Pfizer (9)
United States (508) · Germany (183) · United Kingdom (176) · Canada (142) · Poland (118) · Spain (81) · France (80) · China (73) · South Korea (70) · Hungary (64) · Russia (60) · Bulgaria (58) · Italy (58) · Belgium (55) · Australia (53)
Dave Singh, MD (8) · Stephanie Lee (6) · Esther Garcia, MD (5)
PMID 27881132, PMID 39393433, PMID 33305842, PMID 36472162, PMID 39175217, PMID 21356110, PMID 23861248, PMID 24010736, PMID 24184147, PMID 24432712, PMID 25287629, PMID 25445859, PMID 26001563, PMID 26283085, PMID 26704701, PMID 28639856, PMID 28758192, PMID 31260802, PMID 33217063, PMID 34089147, PMID 34265047, PMID 34773261, PMID 36253275, PMID 36440464, PMID 37934000, PMID 38485149, PMID 39704205, PMID 10387937, PMID 10845940, PMID 10997973, PMID 11222360, PMID 11398072, PMID 11509929, PMID 11756187, PMID 11981005, PMID 12070007, PMID 12931119, PMID 14512314, PMID 15142114, PMID 15251978, PMID 15292060, PMID 15613541, PMID 16046530, PMID 16164444, PMID 16186597, PMID 16239908, PMID 16407509, PMID 16551963, PMID 16788100, PMID 16946302
2009 (20), 2015 (11), 2014 (10), 2017 (9), 2025 (9), 2018 (8), 2008 (7), 2016 (7), 2023 (7), 2019 (6), P30CA015704 (4), P01HL158507 (3), R01HL135235 (3), 2004 (1), 2005 (1)